Related Experiment Videos
Myelography with metrizamide in intraspinal and spinal abnormalities
J F Sackett1, S A Hausserman, H I Okagaki
1Department of Radiology, University of Wisconsin Center for Health Sciences, Madison 53706.
Acta Radiologica. Supplementum
|January 1, 1977
Summary
Metrizamide (Amipaque) myelography is effective for spinal anomalies like Chiari malformations. This contrast agent aids in diagnosing tumors and diastematomyelia, even with complex spinal conditions.
Area of Science:
- Neuroradiology
- Diagnostic Imaging
Background:
- Traditional myelography agents (gas, iophendylate) pose challenges in patients with spinal anomalies.
- Spinal anomalies can complicate the accurate visualization of the subarachnoid space.
Purpose of the Study:
- To evaluate the utility of metrizamide (Amipaque) in myelography for patients with spinal anomalies.
- To assess the safety and efficacy of metrizamide in visualizing the spinal subarachnoid space in complex cases.
Main Methods:
- Metrizamide (Amipaque) was administered to 20 patients with conditions including Chiari malformations, achondroplasia, and scoliosis-related issues.
- Lateral cervical puncture was performed in 10 patients with Chiari malformations.
Main Results:
- Metrizamide myelography provided adequate definition of the spinal subarachnoid space in patients with spinal anomalies.
- The technique successfully demonstrated or excluded associated intraspinal tumors and diastematomyelia.
- Lateral cervical puncture was uncomplicated in the evaluated Chiari malformation cohort.
Conclusions:
- Metrizamide (Amipaque) is a suitable contrast agent for myelography in patients with spinal anomalies.
- It offers improved visualization for diagnosing intraspinal pathologies in complex spinal conditions.
- Metrizamide facilitates accurate diagnosis where conventional methods are difficult.